Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Pulse Biosciences (PLSE) EBIT (2021 - 2025)

Historic EBIT for Pulse Biosciences (PLSE) over the last 5 years, with Q3 2025 value amounting to -$20.4 million.

  • Pulse Biosciences' EBIT fell 4915.42% to -$20.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.9 million, marking a year-over-year decrease of 6268.0%. This contributed to the annual value of -$56.3 million for FY2024, which is 2910.68% down from last year.
  • Pulse Biosciences' EBIT amounted to -$20.4 million in Q3 2025, which was down 4915.42% from -$20.3 million recorded in Q2 2025.
  • Over the past 5 years, Pulse Biosciences' EBIT peaked at -$8.7 million during Q4 2022, and registered a low of -$20.4 million during Q3 2025.
  • Its 5-year average for EBIT is -$14.5 million, with a median of -$14.0 million in 2022.
  • Its EBIT has fluctuated over the past 5 years, first surged by 4464.19% in 2023, then plummeted by 7290.64% in 2025.
  • Over the past 5 years, Pulse Biosciences' EBIT (Quarter) stood at -$15.4 million in 2021, then soared by 43.25% to -$8.7 million in 2022, then plummeted by 43.32% to -$12.5 million in 2023, then plummeted by 61.66% to -$20.3 million in 2024, then fell by 0.52% to -$20.4 million in 2025.
  • Its EBIT was -$20.4 million in Q3 2025, compared to -$20.3 million in Q2 2025 and -$18.0 million in Q1 2025.